Context Therapeutics Faces Nasdaq Delisting Notice as Stock Sinks Below $1.00
CNTX is trading near its 52-week low of $0.545 (10.0% above the low).
Summary
Context Therapeutics received a Nasdaq delisting notice after its stock price fell below $1.00 for 30 consecutive business days. The company has until January 25, 2027, to regain compliance or face delisting.
Key Events · Legal and Risk Events · CNTX
-
Nasdaq Delisting Notice Received
On July 29, 2026, Context Therapeutics received a Nasdaq delisting notice for failing to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.
-
Compliance Deadline Set
The company has an initial 180-day period, until January 25, 2027, to regain compliance by achieving a closing bid price of at least $1.00 for 10 consecutive business days.
-
Potential Second Compliance Period
If the company fails to regain compliance by the initial deadline, it may be eligible for an additional 180-day period, provided it meets certain market value and listing standards and notifies Nasdaq of its intent to cure.
-
Delisting Risk if Compliance Not Achieved
If the company does not regain compliance within the allotted period(s), Nasdaq will issue a delisting notice, which the company may appeal to a Hearings Panel, though success is not assured.
Analysis · CNTX · Life Sciences
A Nasdaq delisting notice landed at Context Therapeutics on July 29, 2026, after its stock closed below $1.00 for 30 consecutive business days. The company now has until January 25, 2027, to regain compliance by sustaining a closing bid price of at least $1.00 for 10 consecutive business days. Should it fall short, delisting could follow, though a second 180-day window may open if certain conditions are satisfied. The notice arrives at a difficult moment: the company recently posted widening losses and accelerating cash burn, and despite encouraging Phase 1 data for its lead candidate CTIM-76, the stock has struggled to hold value. Immediate pressure is mounting to pursue a reverse stock split or other measures to lift the share price, actions that risk significant dilution or operational disruption.
How filings like this one have moved
In the 30 days to Sep 20, 2026, 39.2% of the 344 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNTX was trading at $0.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $55.1M. The 52-week trading range was $0.55 to $3.62. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.